MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Evasion of programmed cell death represents a critical form of oncogene addiction in cancer cells. Understanding the molecular mechanisms underpinning cancer cell survival despite the oncogenic stress could provide a molecular basis for potential therapeutic interventions. Here we explore the role of pro-survival genes in cancer cell integrity during clonal evolution in non-small cell lung cancer (NSCLC). We identify gains of MCL-1 at high frequency in multiple independent NSCLC cohorts, occurring both clonally and subclonally. Clonal loss of functional TP53 is significantly associated with subclonal gains of MCL-1 . In mice, tumour progression is delayed upon pharmacologic or genetic inhibition of MCL-1. These findings reveal that MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MCL-1 is validated as a target in other hematologic malignancies e.g., multiple myeloma13 and non-Hodgkins lymphoma,14 as well as diverse solid tumor malignancies, including lung cancer,15 breast cancer,16 and colon cancer,17 among others.18”
From Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia (2025) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology and management of non-small cell lung cancer
Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018) · Nature · doi:10.1038/nature25183 · Cited by 4,891
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
(2012) · doi:10.1016/j.jmoldx.2011.08.002 · Cited by 2,567
Tracking the Evolution of Non–Small-Cell Lung Cancer
Jamal-Hanjani, M., Wilson, G. A., McGranahan, N., Birkbak, N. J., Watkins, T. B. K., Veeriah, S., Shafi, S., Johnson, D. H., Mitter, R., Rosenthal, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616288 · Cited by 2,349
Self-citationNon-small cell lung cancer: current treatment and future advances
Zappa, C., & Mousa, S. A. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.06.07 · Cited by 1,944
Chen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., Colman, P. M., Day, C. L., Adams, J. M., & Huang, D. C. S. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.12.030 · Cited by 1,816
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Kotschy, A., Szlavik, Z., Murray, J., Davidson, J., Maragno, A. L., Le Toumelin-Braizat, G., Chanrion, M., Kelly, G. L., Gong, J.-N., Moujalled, D. M., et al. (2016) · Nature · doi:10.1038/nature19830 · Cited by 1,047
Self-citationMarino, S., Vooijs, M., van der Gulden, H., Jonkers, J., & Berns, A. (2000) · Genes & Development · doi:10.1101/gad.14.8.994 · Cited by 920
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691
Research works printed but not linked: 23
- Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J. Clinicians 68, 394–424 (2018).
- The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543–550 (2014). · DOI · Paper page
- Janic, A. et al. DNA repair processes are critical mediators of p53-dependent tumor suppression. Nat. Med. 24, 947–953 (2018). · DOI · Paper page
- Lieschke, E., Wang, Z., Kelly, G. L. & Strasser, A. Discussion of some “knowns” and some “unknowns” about the tumour suppressor p53. J. Mol. Cell Biol. 11, 212–223 (2018). · DOI
- Roberts, A. W. et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N. Engl. J. Med 374, 311–322 (2016). · DOI · Paper page
- Fernandez-Marrero, Y., Spinner, S., Kaufmann, T. & Jost, P. J. Survival control of malignant lymphocytes by anti-apoptotic MCL-1. Leukemia 30, 2152–2159 (2016). · DOI
- Borner, M. M. et al. Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer. Br. J. Cancer 79, 952–958 (1999). · DOI
- Zhang, H. et al. Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines. Oncogene 30, 1963–1968 (2011). · DOI · Paper page
- Craig, R. W. et al. Human and mouse chromosomal mapping of the myeloid cell leukemia-1 gene: MCL1 maps to human chromosome 1q21, a region that is frequently altered in preneoplastic and neoplastic disease. Genomics 23, 457–463 (1994). · DOI
- Wesarg, E. et al. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. Int J. Cancer 121, 2387–2394 (2007). · DOI
- Song, L., Coppola, D., Livingston, S., Cress, D. & Haura, E. B. Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biol. Ther. 4, 267–276 (2005). · DOI · Paper page
- Zack, T. I. et al. Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 45, 1134–1140 (2013). · DOI · Paper page
- Kelly, G. L. et al. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes Dev. 28, 58–70 (2014). · DOI · Paper page
- Opferman, J. T. et al. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 426, 671–676 (2003). · DOI · Paper page
- Jackson, E. L. et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15, 3243–3248 (2001). · DOI · Paper page
- Campbell, K. J. et al. MCL-1 is a prognostic indicator and drug target in breast cancer. Cell Death Dis. 9, 19 (2018). · DOI · Paper page
- Brinkmann, K. et al. The combination of reduced MCL-1 and standard chemotherapeutics is tolerable in mice. Cell Death Differ. 24, 2032 (2017). · DOI
- Weber, A. et al. Hepatocyte-specific deletion of the anti-apoptotic protein Mcl-1 triggers proliferation and hepatocarcinogenesis in mice. Hepatology (Baltimore. Md.) 51, 1226–1236 (2010). · DOI · Paper page
- Grabow, S., Delbridge, A. R., Aubrey, B. J., Vandenberg, C. J. & Strasser, A. Loss of a single Mcl-1 allele inhibits MYC-driven lymphomagenesis by sensitizing Pro-B cells to apoptosis. Cell Rep. 14, 2337–2347 (2016). · DOI · Paper page
- Grabow, S., Delbridge, A. R. D., Valente, L. J. & Strasser, A. MCL-1 but not BCL-XL is critical for the development and sustained expansion of thymic lymphoma in p53-deficient mice. Blood 124, 3939 (2014). · DOI · Paper page
- Spinner, S. et al. Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance. Leukemia 30, 1520–1530 (2016). · DOI
- Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinform. 12, 323 (2011). · DOI · Paper page
- Anton, M. & Graham, F. L. Site-specific recombination mediated by an adenovirus vector expressing the Cre recombinase protein: a molecular switch for control of gene expression. J. Virol. 69, 4600 (1995). · DOI · Paper page
Cited by
BCL-2 protein family: attractive targets for cancer therapy
Kaloni, D., Diepstraten, S. T., Strasser, A., & Kelly, G. L. (2023) · Apoptosis · doi:10.1007/s10495-022-01780-7 · Cited by 500
Self-citationApoptotic cell death in disease—Current understanding of the NCCD 2023
Vitale, I., Pietrocola, F., Guilbaud, E., Aaronson, S. A., Abrams, J. M., Adam, D., Agostini, M., Agostinis, P., Alnemri, E. S., Altucci, L., et al. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01153-w · Cited by 361
Self-citationTargeting MCL-1 in cancer: current status and perspectives
Wang, H., Guo, M., Wei, H., & Chen, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01079-1 · Cited by 301
Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia
Hu, X., Li, L., Nkwocha, J., Kmieciak, M., Shang, S., Cowart, L. A., Yue, Y., Horimoto, K., Hawkridge, A., Rijal, A., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02125-x · Cited by 15
Metadata
- Authors
- Munkhbaatar, E., Dietzen, M., Agrawal, D., Anton, M., Jesinghaus, M., Boxberg, M., Pfarr, N., Bidola, P., Uhrig, S., Höckendorf, U., Meinhardt, A.-L., Wahida, A., Heid, I., Braren, R., Mishra, R., Warth, A., Muley, T., Poh, P. S. P., Wang, X., Fröhling, S., Steiger, K., Slotta-Huspenina, J., van Griensven, M., Pfeiffer, F., Lange, S., Rad, R., Spella, M., Stathopoulos, G. T., Ruland, J., Bassermann, F., Weichert, W., Strasser, A., Branca, C., Heikenwalder, M., Swanton, C., McGranahan, N., & Jost, P. J.
- ORCID
- Munkhbaatar, Enkhtsetseg
- Agrawal, Deepti
- Anton, Martina
- Pfarr, Nicole
- Wahida, Adam
- Braren, Rickmer
- Muley, Thomas
- Wang, Xin
- Fröhling, Stefan
- Steiger, Katja
- van Griensven, Martijn
- Lange, Sebastian
- Stathopoulos, Georgios T.
- Ruland, Jürgen
- Strasser, Andreas
- Branca, Caterina
- Heikenwalder, Mathias
- Swanton, Charles
- McGranahan, Nicholas
- Jost, Philipp J.
- Venue
- Nature Communications
- Published
- 2020-09-10
- Volume
- 11
- Issue
- 1
- ISSN
- 2041-1723
- Cited by
- 61
- References
- 16
- Language
- en
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Funders
- Deutsche Krebshilfe (111783)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically. https://app.cochat.ai/papers/10.1038/s41467-020-18372-1
- The paper
- Munkhbaatar, E., Dietzen, M., Agrawal, D., Anton, M., Jesinghaus, M., Boxberg, M., Pfarr, N., Bidola, P., Uhrig, S., Höckendorf, U., Meinhardt, A.-L., Wahida, A., Heid, I., Braren, R., Mishra, R., Warth, A., Muley, T., Poh, P. S. P., Wang, X., . . . Jost, P. J. (2020). MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically. Nature Communications. https://doi.org/10.1038/s41467-020-18372-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.